ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer

PURPOSE: DNA-damaging agents comprise the backbone of systemic treatment for many tumor types; however, few reliable predictive biomarkers are available to guide use of these agents. In muscle-invasive bladder cancer (MIBC), cisplatin-based chemotherapy improves survival, yet response varies widely...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Li, Qiang, Damish, Alexis W., Frazier, Zoë, Liu, David, Reznichenko, Elizaveta, Kamburov, Atanas, Bell, Andrew, Zhao, Huiyong, Jordan, Emmet J., Gao, S. Paul, Ma, Jennifer, Abbosh, Philip H., Bellmunt, Joaquim, Plimack, Elizabeth R., Lazaro, Jean-Bernard, Solit, David B., Bajorin, Dean, Rosenberg, Jonathan E., D’Andrea, Alan D., Riaz, Nadeem, Van Allen, Eliezer M., Iyer, Gopa, Mouw, Kent W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6434536/
https://ncbi.nlm.nih.gov/pubmed/29980530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados